EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Relationship between use of anti‐platelet agents, oral anti‐coagulants, and Aβ burden with cerebral microhemorrhages in cognitively asymptomatic adults

Marcus D Gay, Dobri Baldaranov iD, Michael C Donohue, Clifford R Jack, Reisa A Sperling, Paul S Aisen, Michael S Rafii

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Marcus D Gay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Therapeutic Research Institute, Keck School of Medicine, San Diego, California, USA. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Cerebral Hemorrhage, Platelet Aggregation Inhibitors, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institutes of Health National Institute on Aging, NIA NIH HHS, An anonymous foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Cerebral microhemorrhages (CMHs) are detectable by magnetic resonance imaging (MRI). CMHs in deep brain regions are linked to hypertensive vasculopathy, while those in lobar regions with amyloid beta (Aβ) deposition in blood vessels. This study aims to determine the association between anti‐thrombotic treatment and CMH prevalence among cognitively asymptomatic adults, and to assess the role of Aβ markers, apolipoprotein E ( APOE ) ε4 carrier status, and cardiovascular risk factors in CMH development. METHODS Using baseline data from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, we examined CMH presence via 3T MRI, along with medication use, APOE ε4 carrier status, medical history, and blood pressure. RESULTS Our analysis showed a significantly higher prevalence of CMHs in the A4 cohort (17.3%) compared to the LEARN cohort (2.6%). DISCUSSION Factors such as male sex, age, Aβ markers, and APOE ε4 status were significantly associated with higher CMH prevalence in the A4 cohort. However, anti‐thrombotic treatment did not show association with overall CMHs. Highlights Male sex, age > 75, amyloid beta (Aβ) burden, and apolipoprotein E ( APOE ) ε4 homozygosity are significantly associated with higher prevalence of CMHs (cerebral microhemorrhages) in a cohort of cognitively asymptomatic individuals. Male sex, age > 75, Aβ burden, and APOE ε4 homozygosity are significantly associated with higher prevalence of lobar CMHs in a cohort of cognitively asymptomatic individuals. Anti‐platelet or anti‐coagulant usage were not associated with an increased prevalence of CMHs in either brain location or overall, in a cohort of cognitively asymptomatic individuals. History of a lipid disorder is associated with a higher prevalence of lobar CMHs in a cohort of cognitively asymptomatic individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesCerebral HemorrhagePlatelet Aggregation InhibitorsAnticoagulantsAlzheimer DiseaseHumansMaleFemaleAgedMagnetic Resonance ImagingApolipoprotein E4PrevalenceMiddle AgedRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

amyloid betaanti‐thrombotic treatmentasymptomatic Alzheimer's diseasecerebral amyloid angiopathycerebral microhemorrhages

Substanzen

Amyloid beta-PeptidesPlatelet Aggregation InhibitorsAnticoagulantsApolipoprotein E4

Autor:innen und Institutionen

  • Alzheimer's Therapeutic Research Institute, Keck School of Medicine, San Diego, California, USA.
  • Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology, Harvard Aging Brain Study, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Dobri Baldaranov

Förderung

  • National Institutes of Health National Institute on Aging
  • NIA NIH HHS
  • An anonymous foundation
  • Alzheimer's Association
  • David and Lucile Packard Foundation
  • Foundation for the National Institutes of Health
  • GHR Foundation
  • Eli Lilly and Company

Zitieren

APA

Gay, M. D., Baldaranov, D., Donohue, M. C., Jack, C. R., Sperling, R. A., Aisen, P. S., & Rafii, M. S. (2025). Relationship between use of anti‐platelet agents, oral anti‐coagulants, and Aβ burden with cerebral microhemorrhages in cognitively asymptomatic adults. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70167

Vancouver

Gay MD, Baldaranov D, Donohue MC, Jack CR, Sperling RA, Aisen PS, et al. Relationship between use of anti‐platelet agents, oral anti‐coagulants, and Aβ burden with cerebral microhemorrhages in cognitively asymptomatic adults. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70167

BibTeX
@article{Gay2025,
  author = {Gay, Marcus D and Baldaranov, Dobri and Donohue, Michael C and Jack, Clifford R and Sperling, Reisa A and Aisen, Paul S and Rafii, Michael S},
  title = {Relationship between use of anti‐platelet agents, oral anti‐coagulants, and Aβ burden with cerebral microhemorrhages in cognitively asymptomatic adults},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70167}
}
Kostenlos starten →